Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

Affiliations

• ¹ GlaxoSmithKline plc, Stockley Park West, Uxbridge, Middlesex, UK. margaret.x.tabberer@gsk.com.
• ² GlaxoSmithKline plc, Research Triangle Park, NC, USA.
• ³ GlaxoSmithKline plc, Stockley Park West, Uxbridge, Middlesex, UK.
• ⁴ University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
• ⁵ UCL Respiratory, University College London, London, UK.
• ⁶ GlaxoSmithKline plc, Collegeville, PA, USA.
• ⁷ The Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
• ⁸ The Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁹ Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
• ¹⁰ University of Copenhagen, Copenhagen, Denmark.
• ¹¹ The Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA.
• ¹² University of Michigan, Pulmonary and Critical Care, Ann Arbor, MI, USA.
• ¹³ New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
• ¹⁴ Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.